Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Teva's early Copaxone-switching success turns analysts into believers

11.03.2014 / Fierce Pharma

Early progress doesn't always equal long-term success. But at least in the case of Teva Pharmaceutical Industries–which is firing on all cylinders to convert patients to a new, long-acting version of Copaxone–early results have some analysts thinking the Israeli company may deliver on its promise to switch 30% to 50% of patients.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: